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1. Introduction 
Retroviral vectors derived from the mouse moloney leukemia virus (MLV) are widely used 
for gene therapy of blood disorders because they are capable of permanently integrating a 
therapeutic gene into hematopoietic cells and achieving long-term expression. However, a 
limitation of MLV retroviral vectors is the inability to infect growth-arrested cells. It has 
been demonstrated that a passage through mitosis of infected cells is required for 
productive infection of MLV (Lewis & Emerman 1994). The breakdown of the nuclear 
membrane at mitosis may be necessary for nuclear transport of the oncoretroviral 
preintegration complex which is too large to enter a nuclear pore in the intact nuclear 
membrane. Because most of the target cells of gene therapy such as hematopoietic stem cells 
and lymphocytes are quiescent or rarely dividing, the requirement for cell division limits the 
use of MLV vectors for therapeutic gene transfer. 
For clinical trial of gene therapy, the best-established therapeutic vector is a gamma 
retroviral vector. This retroviral vector system has successfully been used for gene transfer 
to hematopoietic cells to treat X-linked severe combined immunodeficiency (X-SCID) and 
adenosine deaminase deficiency (ADA-SCID). However, in these successful clinical trials, 
genotoxicity mediated by integrated vector proviruses has led to clonal expansion, and in 5 
of 20 of these X-SCID patients have developed T-cell leukemia (Hacein-Bey-Abina et al. 
2008; Hacein-Bey-Abina et al. 2003; Howe et al. 2008). Molecular analyses of the leukemia 
cases showed that these retroviral vectors were integrated into a small number of T-cell 
proto-oncogenes, especially LMO2, leading to its aberrant and high-level expression caused 
by the strong enhancer elements located in the U3 region of the MLV long-terminal repeat 
(LTR). Moreover, the 2 patients with X-linked chronic granulomatous disease (X-CGD) 
exhibited striking clonal dominance with most of their gene-corrected cells having insertions 
into or near of the MDS1-EVI1, PRDM16, or SETBP1 loci (Ott et al. 2006). These retroviral 
vector genotoxicity emphasize that next-generation vectors should further improve the 
safety and the genotoxicity of retroviral integration is a relevant factor to be considered in 
designing vectors for future clinical trials. 
Human immunodeficiency virus type-1 (HIV-1), an etiological agent of acquired 
immunodeficiency syndrome (AIDS), is a member of lentivirinae which is a subfamily of 
retroviruses. We have previously established a packaging system which generates helper 
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free recombinant HIV vectors (Shimada et al. 1991). Compared with widely used 
amphotrophic retroviral vectors, HIV vectors have several interesting features. First, since 
the major receptor for HIV infection is the CD4 molecules of helper T lymphocytes, the HIV 
vectors are capable of targeted gene transfer into CD4+ cells (Miyake et al. 1996; Shimada et 
al. 1991). Second, since gene expression from the HIV-LTR is dependent upon the HIV 
encoded transacting factor TAT (Sodroski et al. 1984), in the presence of TAT, the HIV-LTR 
functions as a very strong promoter. However, because there is no TAT molecule in target 
cells, the HIV-LTR of the integrated provirus is inactive. Inactivation of the LTR of the 
retroviral vector is thought to be important to minimize the chance of insertional activation 
of cellular proto-oncogenes and promoter interference between the LTR and the internal 
promoter. Third, unlike oncoretroviruses, HIV and other lentiviruses have the ability to 
infect and integrate in non-dividing cells. Therefore, HIV based vectors can be used for gene 
transfer into non-dividing cells (Miyake et al. 1998). This possibility is particularly 
important, because none of the current vectors can efficiently integrate into chromosome of 
non-dividing cells. 
In this chapter, we describe about HIV vector pseudotyped with HIV envelopes. 
Replication-incompetent HIV vectors pseudotyped with HIV envelopes (BH10 or SF162) 
were developed and were shown to be capable of targeted gene transfer into CD4+ T cells 
and macrophages. This strict T cell tropism is important for the development of gene 
therapy of AIDS or adult T-cell leukemia (ATL). We also developed an improved strategy 
for preparation of high titer HIV vectors. Since primary un-stimulated T cells and terminally 
differentiated macrophages were transduced with high titer HIV vectors efficiently, HIV 
vectors are useful for the manipulation of gene expression in HIV infectable cells and the 
development of gene therapy targeting lymphocytes and macrophages. Finally, we present 
the application of HIV vectors for AIDS and ATL. 
2. Production and concentration of HIV vectors 
2.1 Plasmid construction 
The first generation packaging plasmid (pCGPE) provided all gag and pol sequences, the 
viral regulatory genes tat and rev and the accessory genes vif, vpr and vpu from T-cell 
tropic HIV strain (BH10) (Ratner et al. 1987). To improve the safety, the single packaging 
plasmid (pCGPE) was divided into two plasmids. One is the pCAGgpR, which contains the 
CAG promoter and HIV gag, pol and RRE; another one is the T-cell tropic HIV env 
expression vector (penvBH10). We also developed macrophage tropic HIV env expression 
vector (penvSF162), which contains the macrophage tropic HIV env fragment from SF162 
(Collman et al. 1989)(Figure 1A).  
The transfer plasmid consists of an expression cassette and the HIV cis-acting factors 
necessary for packaging together with the packaging signal (Ψ). pHXN transfer vector 
plasmid contains the TK promoter and neomycin resistance gene (neoR). To improve the 
packaging efficiency and safety, we modified splicing donor (SD) site (TGGT -> TCGC) and 
initiation codon of gag gene (ATG -> ATC) (pHXNm). Since promoter activity of HIV-LTR is 
Tat dependent, we also developed Tat independent transfer vector by replacement of 5’ U3 
region to CMV promoter (pCHXN). To improve the safety, self-inactivating (SIN) transfer 
vector was developed by deletion of 3’ U3 region (κB-κB-sp1-sp1-sp1-TATA) (pCHXN∆) 
(Figure 1B). 
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Fig. 1. Construction of recombinant HIV packaging (A) and transfer vector (B) plasmids. 
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2.2 Production of HIV vectors 
Recombinant HIV vectors were prepared by transiently transfecting Cos cells (2x106 cells/10 
cm dish) with 10 µg of packaging plasmid (pCGPE) and 10 µg of transfer vector plasmid 
(pHXN) using the CaPO4 coprecipitation method described previously (Miyake et al. 1996; 
Shimada et al. 1991). For a separate packaging system, 7 µg of pCAGgpR, 7 µg of penvBH10 
or penvSF162, and 7 µg of vector plasmids were used. After 48 h, the supernatant was 
collected, passed through a 45-µm filter to remove cell debris. The conditioned medium of 
transfected Cos cells were used as the HIV vector stock (Figure 2). To assess the 
transduction efficiency and cell specificity of the vectors, HeLa, CD4H (CD4+ HeLa), and 
CD4H5 (CD4+ and CCR5+ HeLa) cells were incubated with various dilutions of the viral 
supernatants and cultured in the presence of 1,000 µg/ml active G418 for two weeks. G418 
resistant colonies were calculated and the titer of HIV vector was presented as colony 
forming unit (cfu)/ml. 
 
 
 
Fig. 2. Production of HIV vector pseudotyped with HIV envelope. 
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2.3 Concentration of HIV vectors 
The titer of the HIV vector in Cos cell supernatants is approximately 104 cfu/ml when 
assayed on CD4H cells. This titer is too low to transduce primary CD4+ cells. To overcome 
this problem, we concentrated HIV vectors using sulfonated cellulose column 
chromatography, thereby increasing the titer more than 20-fold (Matsuoka et al. 1998). For 
further improvement, among several possible procedures, we found that ultrafiltration 
using CENTRIPREP columns was highly effective to concentrate HIV particles (Miyake et 
al. 2007b). The titer could be increased four orders of magnitudes (Figure 3). The total 
recovery was more than 80 %. No replication competent cytopathic HIV was detected in 
concentrated vector preparation when assayed on MT2 cell-based syncytium formation 
assay, which is highly sensitive to the cytopathic effect of HIV. 
 
 
 
 
Fig. 3. Concentration of HIV vectors by ultrafiltration. By repeating the concentration step 
several times, we were able to obtain highly concentrated HIV vectors. 
3. Characterization of HIV vectors 
3.1 Targeted gene transfer into CD4-positive cells and macrophages 
To examine the tissue specificity of the vectors, CD4- parental HeLa, CD4H, and  
CD4H5 (CCR5+ CD4H) cells were incubated with the T-cell tropic HIV vector containing 
the neoR gene (HXN-T) or the macrophage tropic HIV vector (HXN-M). The T-cell  
tropic HIV vector selectively transduced CD4+ and CXCR4+ HeLa cells, while the 
macrophage tropic HIV vector transduced CD4+ and CCR5+ HeLa cells. Thus, the HIV 
vector has the same tissue specificity as wild type virus. The titer of HIV vectors 
generated from split packaging plasmids were slightly lower than those generated from 
single packaging plasmids (Table 1). Figure 4 shows the result of transduction of CD4H 
cells with MLV or HIV vector expressing enhanced green fluorescent protein (EGFP) gene 
(MLVG or HXG-T). Selective CD4+ cells were transduced by HXG-T compared to MLVG 
vector. 
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 HeLa CD4H CD4H5 
CD4 - + + 
CXCR4 - + + 
CCR5 - - + 
pCGPE 0 1.2x104 1.1x104 
pCAGgpR+penvBH10 0 0.8x104 0.7x104 
pCAGgpR+penvSF162 0 0 0.4x104 
Table 1. Selective transduction of CD4-positive HeLa cells by HIV vectors 
 
 
Fig. 4. Transduction of CD4-positive HeLa cells by MLV and HIV vectors expressing GFP. 
We next attempted to transduce human primary cells using the high titer HIV vector 
carrying the EGFP gene. After enrichment of CD4+ cells, the cells were stimulated with IL2 
and PHA. Two days after stimulation, transduction was performed using the concentrated 
T-cell tropic HIV vector (HXG-T), and up to 84% of the stimulated T cells were found to be 
transduced. Samples of these transduced lymphocytes were analyzed to determine the 
duration of GFP expression, which was detected for more than one month with no decline in 
the percentage of GFP+ cells (Miyake et al. 2007b). It thus appears that HIV vectors were 
integrated into the chromosomes, and the growth rate of vector-transduced cells was the 
same as that of non-transduced cells, making this highly concentrated HIV vector 
potentially useful for gene transfer into human primary lymphocytes.  
We have reported that HIV vectors are capable of mediating gene transfer into non-dividing 
cells (Miyake et al. 1998). Therefore, we next attempted to transduce freshly isolated, un-
stimulated CD4+ T cells and terminally differentiated macrophages. The un-stimulated T cells 
were also efficiently transduced by HXG-T, with from 20 % to 54 % of the un-stimulated T cells 
being GFP positive, while these un-stimulated T cells could not transduced by MLV based 
retroviral vector. In addition, approximately 20 % of terminally differentiated, monocyte-
derived macrophages were transduced using concentrated the macrophage tropic HIV vector 
expressing EGFP (HXG-M), indicating that macrophage trophic HIV vector should also be 
useful for targeted gene transfer into macrophages (Miyake et al. 2007b). We also construct 
HIV vectors containing LacZ gene and transduced with primary CD4+ T cells and 
macrophages. Figure 5 shows the result of transduction of CD4+ T cells and macrophages with 
HIV vector expressing LacZ gene. X-gal staining showed that both primary T cells and 
macrophages are efficiently transduced by HIV vectors. 
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Fig. 5. Transduction of CD4+ T cells and macrophages with HIV vector expressing LacZ gene 
3.2 In vivo targeted gene transfer 
Targeted gene transfer is essential for safe and efficient gene therapy. Systemic injection of 
targeting vector is considered to be an ideal method of gene transfer. Since HIV vector was 
capable of targeted and efficient gene transfer into CD4+ human cells including non-
stimulated primary CD4+ T-cells, it should be potentially useful for in vivo gene transfer into 
T lymphocytes. To analyze whether the HIV vector could be used for in vivo targeting gene 
transfer, Hu-PBL-NOD-scid mice were prepared by intraperitoneal injection of 1 x 107 
human PBL into NK depleted NOD-scid mice. One ml of the HIV vector stock (HXG-T: 1 x 
108 transduction unit (TU)/ml) was inoculated into the intraperitoneal cavity, and the 
mouse was sacrifices after 10 days. FACS analysis showed that 2-4 % of CD4+ T-cells 
recovered from the peritoneal cavity, peripheral blood, and spleen were transduced with the 
HXG-T vector (Figure 6).  
 
 
Fig. 6. In vivo targeted gene transfer by HIV vector. One ml of the HIV vector containing 
GFP stock (1 x 108 TU/ml) was inoculated into the intraperitoneal cavity of Hu-PBL-NOD-
scid mice, and the mouse was sacrifices after 10 days. Expression of CD4 and GFP were 
analyzed by FACS. 
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These results indicate that HIV vector could be used for in vivo targeted gene transfer into 
CD4+ T-cells. Lymphocytes are important target cells for gene therapy of various disorders. 
Targetable and injectable HIV vectors would greatly facilitate the development of such gene 
therapy strategies. 
4. Applications of HIV vectors 
4.1 Gene therapy for AIDS 
A number of gene therapeutic strategies have been proposed for the treatment of AIDS.  
One approach, intracellular immunization (Baltimore 1988), entails rendering otherwise 
HIV-1-permissive cells resistant to HIV-1 infection by introducing such anti-HIV 
molecules as siRNA, antisense RNAs, ribozymes, RNA decoys, and trans-dominant 
negative mutants.  A second approach entails vaccination using expression vectors for 
viral proteins, and a large scale clinical trial based on MLV vector-mediated transfer of the 
HIV-1 env and rev genes was examined. Finally, a third approach entails the use of a 
suicide gene to induce the death of HIV-1 infected cells, thereby preventing virus spread. 
The herpes simplex virus thymidine kinase (HSV-TK) gene is a most used typical suicide 
gene. HSV-TK acting in concert with cellular kinase specifically converts the prodrug 
gancyclovir (GCV) into highly toxic GCV-triphosphate, which causes DNA polymerase 
chain termination and eventually cell death. To minimize unwanted side effects, it is 
essential to develop a technique that enables tissue-specific gene transfer and expression 
only in targeted cells. 
HIV vectors transduce only human CD4+ lymphocytes and macrophages. Further, when 
used in conjunction with the HIV-LTR, an inducible promoter dependent on the virus 
encoded trans-activator Tat, HIV-based vectors pseudotyped with HIV envelope have the 
potential to mediate targeted gene transfer into HIV-1-permissive cells and for specific 
expression in HIV-1 infected cells. This would appear to make such vectors ideal for use in 
gene therapies against AIDS. Advantages of HIV vector for gene therapy of AIDS are 
summarized in Table 2. 
 
1. Specific gene transfer into HIV infectable cells 
2. Inducible expression on HIV infected cells 
3. HIV vector sequences were packaged into newly synthesized virions 
4. Useful for in vivo targeting gene transfer 
Table 2. Advantages of HIV vector for gene therapy of AIDS 
We constructed an HIV-based vector pseudotyped with HIV envelope containing the 
HSV-TK suicide gene under the control of the inducible HIV-LTR promoter (Figure 7A). 
This vector was selectively transferred into CD4+ cells, and the HSVTK gene was 
subsequently expressed only in HIV-1-infected cells. Consequently, subsequent exposure 
to GCV selectively killed HIV-1 infected cells (Figure 7B). After transduction of H9 cells 
with HXTKN (HXTKN/H9), GCV-sensitivity was analyzed by MTT assay. Prior to HIV-1 
infection, the GCV IC50 in HXTKN/H9 cells was approximately 100 µg/ml. On the other 
hand, HXTKN/H9 cells became highly sensitive to GCV after infection with HIV-1. The 
GCV IC50 of HIV-1-infected HXTKN/H9 cells were 0.1 µg/ml or about 1,000 times greater 
than in uninfected cells (Figure 7C). We next tested the extent to which HIV-1 replication 
was inhibited by the selective suicide of HIV-1-infected cells.  In a model experiment, 
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HIV-1 infected HXTKN/H9 cells were mixed with uninfected HXTKN/H9 cells to a ratio 
of 1:100, and virus replication was studied by measuring p24 (Figure 7D). High levels of 
p24 were detected when the mixed cells were grown in the absence of GCV, but the 
amount of detected p24 declined dramatically following addition of 10 µg/ml GCV, 
indicating that selective suicide of HIV-infected cells effectively inhibited spread of the 
virus. In addition, on HIV-1 infection, HIV vector sequences were packaged into newly 
synthesized virions that were transferred into surrounding untransduced cells. These 
results support the rationale for treatment of HIV infection with HIV-based vectors 
(Miyake et al. 2001). 
 
 
 
 
Fig. 7. Selective killing of HIV infected cells. (A) Inducible HIV vectors containing the HSV-
TK suicide gene. (B) Rationale for treatment of HIV infection with HIV-based vectors. (C) 
HXTKN transduced H9 cells were incubated for 5 days with various concentrations of GCV 
(0.001-100 µg/mL), after which cell growth was estimated by MTT assay. (D) Effect of GCV 
on HIV-1 replication. A mixture of HIV-1-infected and uninfected HXTKN/H9 cells (1:100) 
were cultured with or without 10 µg/ml GCV. After 7 days, p24 levels in the culture 
supernatant were measured by ELISA. 
www.intechopen.com
 Viral Gene Therapy 
 
364 
We also investigated the utility of the HIV vector by intracellular immunization strategy. 
The chemokine receptors, CXCR4 and CCR5 (Alkhatib et al. 1996; Deng et al. 1996; Feng et 
al. 1996), have been identified as co-receptors for HIV-1 infection (Figure 8A). These cellular 
genes are attractive targets for intracellular immunization, because the mutation rate of the 
cellular gene is much less than that of the viral genome. We examined the feasibility of 
antisense inhibition of CXCR4 expression using HIV vector. We constructed the HIV vector 
containing the antisense sequence (738-429 nt) of CXCR4 driven by the CAG promoter and 
transduced CEM cells (Figure 8B). The level of CXCR4 in antisense expressing (HXCXAN-
transduced) CEM cells was reduced up to 20 % of that in control (HXN-transduced) cells 
(Figure 8C). Inhibition of T-cell trophic HIV replication also observed in transduced CEM 
cells (Figure 8D). These results suggest that antisense inhibition of CXCR4 expression is 
effective to block HIV-1 infection at the early step and may be useful for gene therapy of 
HIV-1 infection. 
 
 
 
Fig. 8. Suppression of HIV-1 replication by HIV vector containing antisense CXCR4. (A) 
CXCR4 or CCR5 is a co-receptor of HIV-1 infection. (B) Construction of HIV vector 
expressing antisense CXCR4. (C) Expression of CXCR4 on HXN (control) or HXCXAN-
transduced CEM cells. Expression of CXCR4 was analyzed by FACS. (D) Effect of antisense 
CXCR4 on HIV-1 replication. After HIV-1-infected HXN- or HXCXAN-transduced CEM 
cells were cultured for 7 days, p24 levels in the culture supernatant were measured by 
ELISA. 
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4.2 Development of selective transduction of HIV-1-infected cells 
HIV based vectors bind specifically to the CD4 antigen and are capable of targeted gene 
transfer into CD4+ cells. The strict cell specificity of HIV vectors should be important for 
development of gene therapy of AIDS. However, HIV vectors may not be useful for gene 
transfer into cells already infected with HIV-1, because CD4 expression is usually down-
regulated and in contrast, the HIV envelope glycoprotein (HIV-Env) is overexpressed in 
such cells (Hoxie et al. 1986; Maddon et al. 1986). Therefore, using a special feature of the 
HIV vectors, we have developed a novel strategy for targeted gene transfer into HIV-1 
infected cells based on two-step gene transfer. Figure 9A shows the concept of two-step gene 
transfer. The first step involves the stable introduction of the HIV vector containing the 
ecotrophic MLV receptor (EcoRec) gene into human CD4+ T cells as a molecular switch.  
 
 
 
Fig. 9. Targeted gene transfer into HIV-1 infected cells. (A) Concept of two-step gene 
transfer for selective transduction of HIV-1 infected cells. (B) Inducible expression of EcoRec 
on HXERN transduced CEM cells. The cells were infected (HIV(+)) or uninfected (HIV(-)) 
with HIV-1. (C) HXERN transduced CEM cells were infected (HIV(+)) or uninfected (HIV(-)) 
with HIV-1 and then, transduced with the ecotrophic retroviral vectors containing LacZ 
gene. Expressions of β-galactosidase were assessed by X-gal staining. 
Since the HIV-LTR is Tat-inducible, it is expected that EcoRec is expressed only after HIV-1 
infection. High levels of EcoRec expression were observed only in HIV-1 infected cells. 
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These cells became highly susceptible to ecotrophic MLV infection and therefore, in the 
second step, HIV-1 infected cells were selectively transduced with ecotrophic MLV vectors.  
CEM cells were transduced with the HIV vector containing the EcoRec gene under the 
control of the HIV-LTR (HXERN). Inducible expression of EcoRec in transduced cells was 
studied by the virus binding assay. Prior to HIV-1 infection, no detectable EcoRec was 
observed on the cell surface. However, after HIV-1 infection, high levels of induced EcoRec 
expression were detected by FACS analysis (Figure 9B). These findings indicated that 
HXERN transduced cells were ecotrophic MLV non-permissive, but became highly sensitive 
to ecotrophic MLV infection, once infected with HIV-1. In the next step, HXERN transduced 
cells were incubated with the ecotrophic MLV vector containing the beta-galactosidase gene 
(MLVLacZ). X-gal staining showed that HXERN transduced cells were totally resistant to 
retroviral infection. However, HIV-1 infected HXERN transduced cells were selectively 
transduced with MLVLacZ (Figure 9C). These findings indicate that this two-step method 
can be used for efficient, selective and stable gene transfer into HIV-1 infected cells (Sakai et 
al. 2001). 
A possible clinical application of this strategy is as follows. Targets should be HIV 
seropositive but disease free patients. Most CD4+ T cells in these patients are HIV negative.  
HXERN is stably inserted into these T cells (1st step). After a variable asymptomatic period, 
the virus apparently starts replication and spreads within the whole body. During this stage, 
EcoRec is expressed on the surface of only HIV-1 infected cells. Therefore, HIV-1 infected 
cells can be selectively attacked with the ecotrophic MLV vector carrying the therapeutic 
gene. 
4.3 Gene therapy for ATL 
Adult T cell leukemia (ATL) is a malignant disease etiologically associated with human T 
cell leukemia virus type I (HTLV-I). The prognosis of acute- or lymphoma-type ATL is far 
worse than that of other lymphoid malignancies, and effective therapy has not been 
established. HIV based vectors are capable of targeted and highly efficient gene transfer into 
CD4+ T cells regulated by the HIV envelope glycoprotein gp120 and CD4 interaction.   
Because almost all ATL cells express CD4, HIV based vectors are useful for targeting 
therapeutic genes to ATL cells. We investigated the potential efficacy of treating ATL cells 
using a gene therapeutic approach involving the use of an HSV-TK-mediated suicide 
system.  HIV vectors containing the HSV-TK gene under the control of CMV promoter 
(Figure 10A) were constructed to achieve targeted gene transfer into CD4+ ATL cells, after 
which the transduced cells were selectively killed by treatment with GCV. To examine the 
utility of HIV vectors in vivo, ATL-NOD-SCID mice were prepared by intraperitoneal 
injection of 1×107 MT2 cells into NK-depleted NOD-SCID mice. Thereafter, 1 ml of 
concentrated HIV vector expressing HSV-TK (HXCTKN) or GFP (HXG) stock was injected 
into the intraperitoneal cavity, and GCV was administered twice a day for 5 days (Figure 
10B). After three weeks, plasma sIL2-Rα levels, which are indicator of growth of MT2 cells, 
were significantly lower in mice administered HXCTKN than in those administered control 
HXG. Moreover, HXCTKN-injected mice survived significantly longer than HXG-injected 
mice (Miyake et al. 2007a) (Figure 10C). Taken together, these findings suggest that HIV 
vectors could be used for in vivo targeted gene transfer into ATL cells and thus could serve 
as the basis for the development of effective new therapies for the treatment ATL. 
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Fig. 10. Selective killing of ATL cells by HIV vector expressing HSV-TK gene. (A) 
Construction of HIV vector containing the HSV-TK suicide gene. (B) Experimental design of 
in vivo model for ATL. ATL model mice were prepared by intraperitoneal injection of 1×107 
MT2 cells into NK-depleted NOD-SCID mice. Two days after treatment by HIV vectors 
(HXG or HXCTKN), GCV was administered twice a day for 5 days. (C) Survival curve of 
HIV vector treated ATL model mice. Mice administered HXCTKN-injected survived 
significantly longer than those injected with HXG (p=0.002). 
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5. Summary and future developments 
Tissue-specific gene transfer and expression are crucial for the development of safe and 
effective gene therapy protocols. In that context, HIV-based retroviral vectors pseudotyped 
with HIV envelope have several advantages compared to MLV or VSV pseudotyped HIV 
vector. We succeeded in concentration of HIV vectors and primary CD4+ cells were 
efficiently transduced with high titer HIV vectors. Moreover, HIV vector is potentially 
useful for in vivo gene transfer into T lymphocytes. These findings strongly suggest that 
concentrated HIV vectors should be useful in gene therapies targeting lymphocytes and 
macrophages.  
HIV based retroviral vectors were originally designed for gene therapy in the treatment of 
AIDS. And HIV vector have a lot of advantages of for gene therapy of AIDS (Table. 2). 
Therefore, we developed novel gene therapy strategy for AIDS using our original HIV 
vectors. Tissue specific transduction into HIV-infectable cells and inducible expression of 
HIV-infected cells were achieved by using HIV vector. We used an HIV vector containing 
the HSV-TK gene to selectively kill HIV-1-infected cells and to inhibit HIV-1 replication.  
Although this system may not represent a complete cure for AIDS, combining gene therapy 
with other anti HIV-1 therapies may be useful for the long-term control of the disease.  
Currently, recombinant HIV vectors were prepared by transiently transfecting Cos cells 
with packaging plasmid and transfer vector plasmid using the CaPO4 coprecipitation 
method. Therefore, to make a high titer HIV vector, a large number of cell plate and a lot of 
plasmids are need. A stable packaging system for producing HIV vectors may be useful for 
future clinical applications using HIV vectors. 
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